Search

Your search keyword '"Thanyanan, Reungwetwattana"' showing total 24 results
Start Over Author "Thanyanan, Reungwetwattana" Journal journal of thoracic oncology
24 results on '"Thanyanan, Reungwetwattana"'

2. Lung Cancer in Thailand

Author

Piya Cherntanomwong, Songporn Oranratnachai, Putipun Puataweepong, Thanyanan Reungwetwattana, and Viratch Tangsujaritvijit

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, business.industry, MEDLINE, Thailand, medicine.disease, Risk Factors, Internal medicine, medicine, Humans, business, Lung cancer
Published
2020
Full Text
View/download PDF

3. Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC

Author

Dong Wan Kim, Kevin L.M. Chua, Chia-Chi Lin, Gwo Fuang Ho, Tony Mok, Anthony W.H. Chan, Myung-Ju Ahn, Yong Chan Ahn, Fan Yang, Hiroshi Onishi, Daniel Shao-Weng Tan, Thanyanan Reungwetwattana, Ross A. Soo, Wan Ling Tan, James Chih-Hsin Yang, Lye Mun Tho, and Victor Ho-Fun Lee

Subjects
0301 basic medicine, Pulmonary and Respiratory Medicine, China, medicine.medical_specialty, Consensus, Lung Neoplasms, Taiwan, Disease, 03 medical and health sciences, 0302 clinical medicine, Japan, Thoracic Oncology, Republic of Korea, Health care, medicine, Humans, Stage (cooking), Intensive care medicine, Pulmonologists, Neoplasm Staging, Cancer staging, business.industry, Clinical trial, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Hong Kong, business, Chemoradiotherapy
Abstract

Stage III NSCLC represents a heterogeneous disease for which optimal treatment continues to pose a clinical challenge. Recent changes in the American Joint Commission on Cancer staging to the eighth edition has led to a shift in TNM stage grouping and redefined the subcategories (IIIA-C) in stage III NSCLC for better prognostication. Although concurrent chemoradiotherapy has remained standard-of-care for stage III NSCLC for almost 2 decades, contemporary considerations include the impact of different molecular subsets of NSCLC, and the roles of tyrosine kinase inhibitors post-definitive therapy and of immune checkpoint inhibitors following chemoradiotherapy. With rapid evolution of diagnostic algorithms and expanding treatment options, the need for interdisciplinary input involving multiple specialists (medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists and thoracic surgeons) has become increasingly important. The unique demographics of Asian NSCLC pose further challenges when applying clinical trial data into clinical practice. This includes differences in smoking rates, prevalence of oncogenic driver mutations, and access to health care resources including molecular testing, prompting the need for critical review of existing data and identification of current gaps. In this expert consensus statement by the Asian Thoracic Oncology Research Group, an interdisciplinary group of experts representing Hong Kong, Korea, Japan, Taiwan, Singapore, Thailand, Malaysia, and Mainland China was convened. Standard clinical practices for stage III NSCLC across different Asian countries were discussed from initial diagnosis and staging through to multi-modality approaches including surgery, chemotherapy, radiation, targeted therapies, and immunotherapy.

Published
2020
Full Text
View/download PDF

5. P76.39 Acquired Resistance Mechanisms in T790M-Positive Advanced NSCLC Tested by Non-Invasive Molecular Testing (NIMT) and Their Clinical Relevance

Author

Pimpin Incharoen, Poramate Jiaranai, P. Watcharenwong, Wasun Chantratita, N. Trachu, Bhakbhoom Panthan, Thanyanan Reungwetwattana, D. Munthum, Angkana Charoenyingwattana, and Nareenart Iemwimangsa

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, T790M, Acquired resistance, business.industry, Internal medicine, Non invasive, medicine, Clinical significance, business
Published
2021
Full Text
View/download PDF

7. P2.14-20 ATORG-003: Dacomitinib With or Without Dose Titration as First-Line Therapy for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)

Author

Daniel Shao-Weng Tan, A. Tan, H. Loong, Tony Mok, Chee Khoon Lee, Thanyanan Reungwetwattana, Ross A. Soo, J.C.-H. Yang, and D. Kim

Subjects
Pulmonary and Respiratory Medicine, Dose titration, business.industry, Mutant, non-small cell lung cancer (NSCLC), medicine.disease, Dacomitinib, chemistry.chemical_compound, First line therapy, Oncology, chemistry, Cancer research, medicine, business
Published
2019
Full Text
View/download PDF

9. P2.04-78 PD-L1 Expression as a Prognostic Marker for Non-Small Cell Lung Cancer in Distinct Mutational Status

Author

Pimtip Sanvarinda, Pimpin Incharoen, S. Detarkom, Wasun Chantratita, N. Trachu, Thanyanan Reungwetwattana, Songporn Oranratnachai, and Nareenart Iemwimangsa

Subjects
Pulmonary and Respiratory Medicine, Oncology, business.industry, medicine, Cancer research, Mutational status, Pd l1 expression, Non small cell, Lung cancer, medicine.disease, business
Published
2019
Full Text
View/download PDF

10. Scientific Advances in Lung Cancer 2015

Author

Prasad S. Adusumilli, Giorgio V. Scagliotti, Kenneth E. Rosenzweig, Solange Peters, Daniel R. Gomez, Murry W. Wynes, Graham W. Warren, Paul A. Bunn, Ramón Rami-Porta, Harry J. de Koning, Heather A. Wakelee, Chunxue Bai, Gail Darling, Ronan J. Kelly, Vassiliki A. Papadimitrakopoulou, Fred R. Hirsch, Mary W. Redman, Julie R. Brahmer, Pasi A. Jänne, David R. Gandara, Hisao Asamura, Yang Zhou, Roy S. Herbst, Robert Pirker, Thanyanan Reungwetwattana, Ming-Sound Tsao, Stefan Zimmermann, Annette McWilliams, Anne S. Tsao, Tony Mok, Harvey I. Pass, A. Uraujh Yousaf-Khan, Paul Van Schil, Julien Mazieres, Sai-Hong Ignatius Ou, David P. Carbone, Suresh S. Ramalingam, and Public Health

Subjects
0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Staging, Lung Neoplasms, medicine.medical_treatment, Disease, Treatment of lung cancer, Smoking cessation, Gene mutation, Cancer prevention, Targeted therapy, 03 medical and health sciences, 0302 clinical medicine, SDG 3 - Good Health and Well-being, Internal medicine, Pathology, medicine, Humans, Precision Medicine, Lung cancer, Adjuvant chemotherapy, Biomarkers, Gene mutations, Immunotherapy, Master protocols, Radiotherapy, Screening, Surgery, Value of therapy, business.industry, respiratory system, medicine.disease, Radiation therapy, 030104 developmental biology, 030220 oncology & carcinogenesis, Quality of Life, Human medicine, business
Abstract

Lung cancer continues to be a major global health problem; the disease is diagnosed in more than 1.6 million new patients each year. However, significant progress is underway in both the prevention and treatment of lung cancer. Lung cancer therapy has now emerged as a "role model" for precision cancer medicine, with several important therapeutic breakthroughs occurring during 2015. These advances have occurred primarily in the immunotherapy field and in treatments directed against tumors harboring specific oncogenic drivers. Our knowledge about molecular mechanisms for oncogene-driven tumors and about resistance to targeted therapies has increased quickly over the past year. As a result, several regulatory approvals of new agents that significantly improve survival and quality of life for patients with lung cancer who have advanced disease have occurred. The International Association for the Study of Lung Cancer has gathered experts in different areas of lung cancer research and management to summarize the most significant scientific advancements related to prevention and therapy of lung cancer during the past year. (C) 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Published
2016
Full Text
View/download PDF

11. Laying the Groundwork to Confront the Final Frontier of CNS Metastasis in NSCLC with Targetable Driver Mutations

Author

Sai-Hong Ignatius Ou and Thanyanan Reungwetwattana

Subjects
Pulmonary and Respiratory Medicine, Pathology, medicine.medical_specialty, business.industry, respiratory tract diseases, 03 medical and health sciences, 0302 clinical medicine, Oncology, CNS metastasis, 030220 oncology & carcinogenesis, Mutation (genetic algorithm), Cancer research, Medicine, 030212 general & internal medicine, business
Published
2016
Full Text
View/download PDF

14. P3.09-10 Circulating Cell-Free DNA (cfDNA) Molecular Profile of Thai NSCLC Patients Using Difference Variant Frequency of NGS

Author

Wasun Chantratita, L. Arsa, S. Detarkom, S. Techasurungkul, N. Monnamo, Pimpin Incharoen, Angkana Charoenyingwattana, V. Pairoj, N. Trachu, S. Lukrak, Nareenart Iemwimangsa, and Thanyanan Reungwetwattana

Subjects
Pulmonary and Respiratory Medicine, Oncology, business.industry, Cancer research, Medicine, Molecular Profile, business, Circulating Cell-Free DNA
Published
2018
Full Text
View/download PDF

15. P3.09-08 Tumor Heterogeneity and Molecular Profile of NSCLC in Thai Population

Author

Nareenart Iemwimangsa, Pimpin Incharoen, K. Kamprerasart, A. Jinawat, P. Tienchainaanda, K. Sararat, N. Prasongsook, Wasun Chantratita, Thanyanan Reungwetwattana, S. Detarkom, and N. Trachu

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Internal medicine, Thai population, Medicine, Molecular Profile, business, Tumor heterogeneity
Published
2018
Full Text
View/download PDF

17. Brief Report: A Phase II 'Window-of-Opportunity' Frontline Study of the mTOR Inhibitor, Temsirolimus Given as a Single Agent in Patients with Advanced NSCLC, an NCCTG Study

Author

James R. Jett, Grace K. Dy, R. F. Luyun, Thanyanan Reungwetwattana, Steven E. Schild, Nicholas F. Reuter, Julian R. Molina, Alex A. Adjei, Randolph S. Marks, Kendrith M. Rowland, Sumithra J. Mandrekar, and Katie Allen-Ziegler

Subjects
Male, Oncology, Temsirolimus, Lung Neoplasms, Immunoenzyme Techniques, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Tumor Cells, Cultured, Phosphorylation, Aged, 80 and over, 0303 health sciences, Advanced non–small-cell lung carcinoma, Ribosomal Protein S6 Kinases, 70-kDa, Middle Aged, Prognosis, Rash, 3. Good health, 030220 oncology & carcinogenesis, Female, medicine.symptom, medicine.drug, Adult, Pulmonary and Respiratory Medicine, mTOR inhibitors, medicine.medical_specialty, Nausea, Article, 03 medical and health sciences, Window of opportunity, Internal medicine, Biomarkers, Tumor, medicine, Carcinoma, Humans, Lung cancer, Adverse effect, Protein Kinase Inhibitors, Survival rate, Aged, 030304 developmental biology, Sirolimus, business.industry, PTEN Phosphohydrolase, medicine.disease, Surgery, Clinical trial, business, Proto-Oncogene Proteins c-akt
Abstract

Background: In an effort to evaluate the single agent activity of temsirolimus in previously untreated non–small-cell lung cancer, the North Central Cancer Treatment Group undertook a frontline "window-of-opportunity" study. Methods: Patients received 25 mg of temsirolimus administered intravenously as a weekly 30 minute infusion, on a 4-week cycle. Based on a two-stage Fleming design, the treatment would be promising if at least four of the first 25 evaluable patients in stage I or at least six of the 50 evaluable patients at the end of stage II have a confirmed response. Fresh tumor biopsies were obtained to evaluate predictive markers of temsirolimus activity. Results: A total of 55 patients were enrolled with 52 patients being evaluable. The median age was 64 years. Adverse events (grade 3/4) occurring in 33 patients included dyspnea (12%), fatigue (10%), hyperglycemia (8%), hypoxia (8%), nausea (8%), and rash/desquamation (6%). The clinical benefit rate was 35% with four patients achieving a confirmed partial response and 14 patients with stable disease for 8 weeks or more. The 24-week progression-free survival rate was 25%. Median progression-free survival and overall survival were 2.3 and 6.6 months, respectively. Expression of p70s6 kinase, phospho-p70s6 kinase, Akt, phospho-Akt, and phosphatase and tensin homolog mutation did not correlate with clinical outcome. Conclusions: Temsirolimus given as a single agent in frontline therapy in patients with non–small-cell lung cancer was tolerable and demonstrated clinical benefit but did not meet the primary objective in this study. Patient selection will be needed to enhance the efficacy.

Published
2012
Full Text
View/download PDF

18. OA 11.04 Effect of Early Palliative Care on Aggressiveness of Cancer Care near End of Life in Lung Cancer Patient

Author

Viratch Tangsujaritvijit, V. Sachdev, Thanyanan Reungwetwattana, Jitprapa Konmun, W. Chanprasertpinyo, S. Chaiviboontham, S. Semsarn, Nuttapong Ngamphaiboon, and Pichai Chansriwong

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Palliative care, Oncology, business.industry, Medicine, Cancer, business, medicine.disease, Intensive care medicine, Lung cancer
Published
2017
Full Text
View/download PDF

19. P3.09-19 Matched Thai Lung Cancer Patients Tissue and cfDNA Molecular Profile by NGS

Author

Pimpin Incharoen, K. Kamprerasart, N. Trachu, S. Detarkom, E. Sirachainan, L. Arsa, Wasun Chantratita, Nareenart Iemwimangsa, Thanyanan Reungwetwattana, and Dittapol Muntham

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Internal medicine, medicine, Molecular Profile, Lung cancer, medicine.disease, business
Published
2018
Full Text
View/download PDF

20. P3.15-24 Ramathibodi Lung Cancer Consortium (RLC) Model: Multidisciplinary Team Approach Improves Lung Cancer Patients’ Survival Outcome

Author

A. Kositwattanarerk, Pimpin Incharoen, T. Ativitavas, M. Ngodngamthaweesuk, C. Nitiwarangkul, Putipun Puataweepong, E. Sirachainan, W. Sukkasem, Parinya Leelayana, Piya Cherntanomwong, R. Ruaungkanchanasetr, Somjai Dangprasert, Pichai Chansriwong, N. Aulmongkon, N. Darayen, B. Wetchaphan, Thanyanan Reungwetwattana, Viratch Tangsujaritvijit, Siam Khajarern, T. Suwattanapongched, Wichana Chamroonrat, and Thiti Swangsilpa

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Internal medicine, medicine, Multidisciplinary team, Lung cancer, medicine.disease, business, Survival outcome
Published
2018
Full Text
View/download PDF

21. P3.03-020 Unique Molecular Profile of NSCLC in Thai Population

Author

S. Lukrak, Angkana Charoenyingwattana, Nareenart Iemwimangsa, W. Klaisuban, R. Panvichien, E. Sirachainan, T. Sirisinha Dejthevaporn, Objoon Trachoo, S. Techasurungkul, M. Ngodnbamthaweesuk, S. Detarkom, N. Prasongsook, Thanyanan Reungwetwattana, Chutatip Srichunrusami, Pimpin Incharoen, A. Jinawat, Pareena Janchompoo, Wasun Chantratita, I. Senson, P. Tienchainaanda, Wantanit Pairoj, and N. Trachu

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Internal medicine, Thai population, medicine, Molecular Profile, business
Published
2017
Full Text
View/download PDF

23. P3.01-042 Efficacy & Tolerability of Afatinib in NSCLC Patients Prior Exposure to 1st Generation EGFR TKI: Thailand Multicenter Study

Author

Busyamas Chewaskulyong, Arunee Dechaphunkul, N. Poovorawan, Dittapol Muntham, Virote Sriuranpong, S. Detarkom, W. Lamlertthon, Thanyanan Reungwetwattana, S. Laohavinij, and Vichien Srimuninnimit

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Afatinib, Egfr tki, Multicenter study, Tolerability, Internal medicine, Medicine, business, Intensive care medicine, medicine.drug
Published
2017
Full Text
View/download PDF

24. P3.02b-017 Sequence of EGFR-TKI Therapy and BIM Deletion Polymorphism Affect the Outcome of Treatment in EGFR Positive NSCLC

Author

Chanchai Charonpongsuntorn, N. Trachu, Thanyanan Reungwetwattana, Kaettipong Kampreasart, Sakdiat Saowapa, Ekaphop Sirichainan, Dittapol Muntham, and Pimpin Incharoen

Subjects
0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, Genetics, medicine.medical_specialty, business.industry, 03 medical and health sciences, Egfr tki, 030104 developmental biology, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Medicine, business
Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results